Endocrinology and Metabolism

Original Articles

Clinical Study
Clinical Implication of World Health Organization Classification in Patients with Follicular Thyroid Carcinoma in South Korea: A Multicenter Cohort Study: Meihua Jin, Eun Sook Kim, Bo Hyun Kim, Hee Kyung Kim, Hyon-Seung Yi, Min Ji Jeon, Tae Yong Kim, Ho-Cheol Kang, Won Bae Kim, Young Kee Shong, Mijin Kim, Won Gu Kim; Endocrinol Metab. 2020;35(3):618-627. Published online September 22, 2020; DOI: https://doi.org/10.3803/EnM.2020.742

5,419 View
121 Download
8 Web of Science
9 Crossref

Background
The study aimed to compare the prognostic value of the 4th edition of World Health Organization classification (WHO-2017) with the previous WHO classification (WHO-2004) for follicular thyroid carcinoma (FTC).
Methods
This multicenter retrospective cohort study included 318 patients with FTC from five tertiary centers who underwent thyroid surgery between 1996 and 2009. We evaluated the prognosis of patients with minimally invasive (MI), encapsulated angioinvasive (EA), and widely invasive (WI) FTC according to WHO-2017. Further, we evaluated the proportion of variation explained (PVE) and Harrell’s C-index to compare the predictability of disease-free survival (DFS) and disease-specific survival (DSS).
Results
In total, 227, 58, and 33 patients had MI-, EA-, and WI-FTC, respectively. During a median follow-up of 10.6 years, 46 (14.5%) patients had disease recurrence and 20 (6.3%) patients died from FTC. The 10-year DFS rates of patients with MI-, EA-, and WI-FTC were 91.1%, 78.2%, and 54.9%, respectively (P<0.001, PVE=7.1%, C-index=0.649). The corresponding 10-year DSS rates were 95.9%, 93.5%, and 73.5%, respectively (P<0.001, PVE=2.6%, C-index=0.624). The PVE and C-index values were higher using WHO-2017 than using WHO-2004 for the prediction of DFS, but not for DSS. In multivariate analysis, older age (P=0.02), gross extrathyroidal extension (ETE) (P=0.003), and distant metastasis (P<0.001) were independent risk factors for DSS.
Conclusion
WHO-2017 improves the predictability of DFS, but not DSS, in patients with FTC. Distant metastasis, gross ETE and older age (≥55 years) were independent risk factors for DSS.

Citations

Citations to this article as recorded by

Association of Ultrasonography Features of Follicular Thyroid Carcinoma With Tumor Invasiveness and Prognosis Based on WHO Classification and TERT Promoter Mutation
Myoung Kyoung Kim, Hyunju Park, Young Lyun Oh, Jung Hee Shin, Tae Hyuk Kim, Soo Yeon Hahn
Korean Journal of Radiology.2024; 25(1): 103. CrossRef
Clinical Outcomes and Implications of Radioactive Iodine Therapy on Cancer-specific Survival in WHO Classification of FTC
Genpeng Li, Ziyang Ye, Tao Wei, Jingqiang Zhu, Zhihui Li, Jianyong Lei
The Journal of Clinical Endocrinology & Metabolism.2024;[Epub] CrossRef
Radioiodine whole body scan pitfalls in differentiated thyroid cancer
Cristina Basso, Alessandra Colapinto, Valentina Vicennati, Alessandra Gambineri, Carla Pelusi, Guido Di Dalmazi, Elisa Lodi Rizzini, Elena Tabacchi, Arber Golemi, Letizia Calderoni, Stefano Fanti, Uberto Pagotto, Andrea Repaci
Endocrine.2024;[Epub] CrossRef
The Prognostic Impact of Extent of Vascular Invasion in Follicular Thyroid Carcinoma
David Leong, Anthony J. Gill, John Turchini, Michael Waller, Roderick Clifton‐Bligh, Anthony Glover, Mark Sywak, Stan Sidhu
World Journal of Surgery.2023; 47(2): 412. CrossRef
TERT Promoter Mutation as a Prognostic Marker in Encapsulated Angioinvasive and Widely Invasive Follicular Thyroid Carcinomas
Yasuhiro Ito, Takashi Akamizu
Clinical Thyroidology.2023; 35(5): 202. CrossRef
Risk factors for death of follicular thyroid carcinoma: a systematic review and meta-analysis
Ting Zhang, Liang He, Zhihong Wang, Wenwu Dong, Wei Sun, Ping Zhang, Hao Zhang
Endocrine.2023; 82(3): 457. CrossRef
Molecular classification of follicular thyroid carcinoma based on TERT promoter mutations
Hyunju Park, Hyeong Chan Shin, Heera Yang, Jung Heo, Chang-Seok Ki, Hye Seung Kim, Jung-Han Kim, Soo Yeon Hahn, Yun Jae Chung, Sun Wook Kim, Jae Hoon Chung, Young Lyun Oh, Tae Hyuk Kim
Modern Pathology.2022; 35(2): 186. CrossRef
Whole-genome Sequencing of Follicular Thyroid Carcinomas Reveal Recurrent Mutations in MicroRNA Processing Subunit DGCR8
Johan O Paulsson, Nima Rafati, Sebastian DiLorenzo, Yi Chen, Felix Haglund, Jan Zedenius, C Christofer Juhlin
The Journal of Clinical Endocrinology & Metabolism.2021; 106(11): 3265. CrossRef
Clinicopathological Characteristics and Disease-Free Survival in Patients with Hürthle Cell Carcinoma: A Multicenter Cohort Study in South Korea
Meihua Jin, Eun Sook Kim, Bo Hyun Kim, Hee Kyung Kim, Yea Eun Kang, Min Ji Jeon, Tae Yong Kim, Ho-Cheol Kang, Won Bae Kim, Young Kee Shong, Mijin Kim, Won Gu Kim
Endocrinology and Metabolism.2021; 36(5): 1078. CrossRef

Surgical Findings of Benign Thyroid Nodule, Not Decreased After Thyroxine Suppression Therapy.: Dong Won Byun, Myung Hi Yoo, Kyo Il Suh, Hae Kyung Lee, Guk Bae Kim; J Korean Endocr Soc. 1996;11(4):401-408. Published online November 7, 2019

1,039 View
19 Download

Abstract PDF: Background
Fine needle aspiration and biopsy(FNAB) has known the most accurate test(about 90%) in the preoperative evaluation of patients with a thyroid nodule. The false negative findings of thyroid cancer by FNAB are mainly due to the aspiration of cystic fluid in cystic degeneration of thyroid cancer and the ipossibility of differentiation between follicular adenoma and carcinoma by aspiration or FNAB because of the failure to evaluate the capsule invasion or angioinvasion of the tumor. Actually more than 80% of the nodules are found as benign nodules in aspiration or FNAB and the findings of follieular lesions are found about half of the samples tested, so limiting the cancer incidence in surgically resected samples up to 50% of the surgical resection. Sa reasonable guidelines to manage the benign nodules on aspiration or FNAB are needed which can select the maligna~nt nodules with false negative findings on aspiration or FNAB. We tried to evaluate whether the thyroxine suppression therapy can increase the malignancy rates on thyroidectomy, Methods: We treated the benign thyroid nodules in FNAB with thyroxine for 1 year and cornpared the nodule volume change before and after treatment (every 6 month) with ultrasonogram. We performed thyroidectomy on 1~7 thyroid nodules wbich showed less than 50% decrease of nodule volume after 1 year of thyroxine suppression therapy. Results: The results were as follows. 1) Of all 17 patients, surgical resection revealed malignant thyroid nodule(Group I) in 10 cases (58.82%, papillary cancer. 6 cases, follicular cancer: 4 cases) and benign thyroid nodule(Group II) in 7 cases(41.18%, follicular adenoma: 4 cases, adenomatous goiter: 3 cases). 2) Between group I and II, there was no significant differences in serum T, T and TSH levels before and after thyroxine suppression therapy. Also, there were no significant difference in TSH suppression % between group I and group II(5.60+5.39%, 14.64+11.48%, respectively). 3) Thyroid nodule volume decrease percent before and after thyroxi~ne therapy showed no significant difference between group I and group II (124.80+54.18% vs 159.42+79.82%, p>0.05). Conclusion: Our data suggested that the benign thyroid nodules on aspiration or FNAB which were not suppressed in volume after thyroixine therapy revealed more than 50% incidence of malignancy on surgical resection, so these nodules were highly reeommended to surgical exploration.

Case Report

A Case of Follicular Carcinoma Associated with Hashimoto's Thyroiditis Arising in a Thyroglossal Duct Remnant.: Jin Choi, Jun Cheol Lee, Sun Mi Park, Tae Joon Cha, Hark Rim, Young Sik Choi, Yo Han Park, Hee Kyung Chang; J Korean Endocr Soc. 1996;11(3):336-342. Published online November 7, 2019

1,181 View
24 Download

Abstract PDF: Thyroglossal duct remnants are common congenital abnormalities of the thyroid development but malignant tumors arising in the thyroglossal duct remnants are rare, occuring in less than 1%. In the literature, about 160 cases of malignancy in the thyroglossal duct remnant have been reported. Among the various types of carcinoma being found from the thyroglossal duct remnants, most are papillary carcinoma(79.8%) and Mixed follicular-papillary carcinoma(9.5%). Others are squamous cell carcinoma(7.6%), follicular carcinoma(1.2%), and anaplastic carcinoma(0.6%). Hashimotos thyroiditis is a common autoimmune disease of the thyroid gland. Malignant tumors of the thyroid gland with Hashimotos thyroiditis are rare disorder except malignant lymphoma whose association with Hashimotos thyroiditis is well known. Malignant tumors associated with Hashimotos thyroiditis arising in a thyroglossal duct remnant are extremely rare. Recently the authors experienced a case of follicular carcinoma associated with Hashimotos thyroiditis arising in a thyroglossal duct remnant, which was removed by local excision and reported with literature review.

Namgok Lecture 2018

Thyroid
Genomic Characterization of Differentiated Thyroid Carcinoma: Young Shin Song, Young Joo Park; Endocrinol Metab. 2019;34(1):1-10. Published online March 21, 2019; DOI: https://doi.org/10.3803/EnM.2019.34.1.1

7,096 View
210 Download
36 Web of Science
36 Crossref

Abstract PDF PubReader ePub

Since the release of The Cancer Genome Atlas study of papillary thyroid carcinoma (PTC) in 2014, additional genomic studies of differentiated thyroid carcinoma (DTC) using massively-parallel sequencing (MPS) have been published. Recent advances in MPS technology have started to provide important insights into the molecular pathogenesis of DTC. In the genomic landscape, the most recurrently altered genes in DTC, which has a low mutational burden relative to other cancers, are BRAF, RAS, and fusion genes. Some novel driver candidates also have been identified. The frequency of these genomic alterations varies across the subtypes of DTC (classical PTC, follicular variant of PTC, and follicular thyroid carcinoma). Telomerase reverse transcriptase (TERT) promoter mutations are the alteration that makes the most important contribution to the progression of DTC. In the transcriptomic landscape, DTC can be classified according to its gene expression profile, and each subtype has a distinct mutational profile, intracellular signaling output, and clinicopathological characteristics. Herein, we review the results of genomic studies using MPS technology, and describe the types and frequencies of genomic alterations according to histological classifications of DTC and the characteristics and significance of the gene expression signatures of DTC.

Citations

Citations to this article as recorded by

Radiation-Related Thyroid Cancer
Vladimir Saenko, Norisato Mitsutake
Endocrine Reviews.2024; 45(1): 1. CrossRef
TERT RNAscope analysis of sub-centimetric papillary thyroid carcinomas and synchronous lymph node metastases
Marie-Lisa Eich, Wiebke Jeske, Uschi Zenz, Costanza Chiapponi, Christina Alidousty, Sabine Merkelbach-Bruse, Reinhard Büttner, Anne M. Schultheis
Thyroid Research.2024;[Epub] CrossRef
Molecular testing in fine‐needle aspiration of thyroid nodules
Valarie McMurtry, Sule Canberk, Georgios Deftereos
Diagnostic Cytopathology.2023; 51(1): 36. CrossRef
A Triumvirate:
Jaylou M. Velez Torres, Youley Tjendra, Darcy A. Kerr
Surgical Pathology Clinics.2023; 16(1): 1. CrossRef
Current Status and Prospects of Chemotherapy in Treatment of Distant Metastatic or Recurrent Thyroid Cancer
T. Yamazaki
Nihon Kikan Shokudoka Gakkai Kaiho.2023; 74(2): 141. CrossRef
FDG uptake reflects an immune‐enriched subtype of thyroid cancer: Clinical implications of imaging‐based molecular characterization
Hoon Young Suh, Hongyoon Choi, Sun Wook Cho, Jin Chul Paeng, Gi Jeong Cheon, Young Joo Park, Keon Wook Kang
Cancer Medicine.2023; 12(16): 17068. CrossRef
Advances in transcriptomics and proteomics in differentiated thyroid cancer: An updated perspective (Review)
Shici Yang, Gaohong Zhu, Rui He, Dong Fang, Jiaojiao Feng
Oncology Letters.2023;[Epub] CrossRef
Different Molecular Phenotypes of Progression in BRAF- and RAS-Like Papillary Thyroid Carcinoma
Jinsun Lim, Han Sai Lee, Jiyun Park, Kyung-Soo Kim, Soo-Kyung Kim, Yong-Wook Cho, Young Shin Song
Endocrinology and Metabolism.2023; 38(4): 445. CrossRef
Anaplastic thyroid cancer: Pathogenesis, prognostic factors and genetic landscape (Review)
Abdul-Mohsen Alhejaily, Omar Alhuzim, Yazeed Alwelaie
Molecular and Clinical Oncology.2023;[Epub] CrossRef
Comparative Analysis of Driver Mutations and Transcriptomes in Papillary Thyroid Cancer by Region of Residence in South Korea
Jandee Lee, Seonhyang Jeong, Hwa Young Lee, Sunmi Park, Meesson Jeong, Young Suk Jo
Endocrinology and Metabolism.2023; 38(6): 720. CrossRef
Problems of follicular thyroid carcinoma diagnostics
S. E. Titov, S. A. Lukyanov, S. V. Sergiyko, Yu. A. Veryaskina, T. E. Ilyina, E. S. Kozorezov, S. L. Vorobyov
Head and Neck Tumors (HNT).2023; 13(3): 10. CrossRef
Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies
María San Román-Gil, Javier Pozas, Diana Rosero-Rodríguez, Jesús Chamorro-Pérez, Álvaro Ruiz-Granados, Ignacio Ruz Caracuel, Enrique Grande, Javier Molina-Cerrillo, Teresa Alonso-Gordoa
Cancer Treatment Reviews.2022; 105: 102372. CrossRef
Non-Iodine-Avid Disease Is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer With Papillary Histology
Myat Han Soe, Janet M Chiang, Robert R Flavell, Elham Khanafshar, Laura Mendoza, Hyunseok Kang, Chienying Liu
The Journal of Clinical Endocrinology & Metabolism.2022; 107(8): e3206. CrossRef
Recent Improvements in the Treatment of High-Risk Thyroid Cancer
Eun Kyung Lee
Korean Society for Head and Neck Oncology.2022; 38(1): 1. CrossRef
Prognosis of Patients with 1–4 cm Papillary Thyroid Cancer Who Underwent Lobectomy: Focus on Gross Extrathyroidal Extension Invading Only the Strap Muscles
Ahreum Jang, Meihua Jin, Won Woong Kim, Min Ji Jeon, Tae-Yon Sung, Dong Eun Song, Tae Yong Kim, Ki-Wook Chung, Won Bae Kim, Young Kee Shong, Yu-Mi Lee, Won Gu Kim
Annals of Surgical Oncology.2022; 29(12): 7835. CrossRef
Tackling Thyroid Cancer in Europe—The Challenges and Opportunities
Denis Horgan, Dagmar Führer-Sakel, Paula Soares, Clara V. Alvarez, Laura Fugazzola, Romana T. Netea-Maier, Barbara Jarzab, Marta Kozaric, Beate Bartes, James Schuster-Bruce, Luigino Dal Maso, Martin Schlumberger, Furio Pacini
Healthcare.2022; 10(9): 1621. CrossRef
The role of EZH1 and EZH2 in development and cancer
Soo Hyun Lee, Yingying Li, Hanbyeol Kim, Seounghyun Eum, Kyumin Park, Chul-Hwan Lee
BMB Reports.2022; 55(12): 595. CrossRef
The mutation profile of differentiated thyroid cancer coexisting with undifferentiated anaplastic cancer resembles that of anaplastic thyroid cancer but not that of archetypal differentiated thyroid cancer
Justyna Mika, Wojciech Łabaj, Mykola Chekan, Agata Abramowicz, Monika Pietrowska, Andrzej Polański, Piotr Widłak
Journal of Applied Genetics.2021; 62(1): 115. CrossRef
Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer
Ying Wang, Zhigang Hu, Weiyuan Ma, Yong Niu, Jingwei Su, Lingxiang Zhang, Pengxin Zhao
Investigational New Drugs.2021; 39(3): 764. CrossRef
Thyroid Cancer Identified After Positron Emission Tomography (PET) Shows Aggressive Histopathology
Tim Beck, Ning Zhang, Akeesha Shah, Sarah Khoncarly, Christopher McHenry, Judy Jin
Journal of Surgical Research.2021; 260: 245. CrossRef
Associations between artificial light at night and risk for thyroid cancer: A large US cohort study
Dong Zhang, Rena R. Jones, Peter James, Cari M. Kitahara, Qian Xiao
Cancer.2021; 127(9): 1448. CrossRef
Association of Hyperparathyroidism and Papillary Thyroid Cancer: A Multicenter Retrospective Study (Endocrinol Metab 2020;35:925-32, Chaiho Jeong et al.)
Chaiho Jeong, Jeonghoon Ha, Moo Il Kang
Endocrinology and Metabolism.2021; 36(1): 205. CrossRef
Intratumoral Heterogeneity in Differentiated Thyroid Tumors: An Intriguing Reappraisal in the Era of Personalized Medicine
Antonio Ieni, Roberto Vita, Cristina Pizzimenti, Salvatore Benvenga, Giovanni Tuccari
Journal of Personalized Medicine.2021; 11(5): 333. CrossRef
Silencing circRNA protein kinase C iota (circ-PRKCI) suppresses cell progression and glycolysis of human papillary thyroid cancer through circ-PRKCI/miR-335/E2F3 ceRNA axis
Yan Liu, Gen Chen, Bo Wang, Hanjin Wu, Yi Zhang, Hui Ye
Endocrine Journal.2021; 68(6): 713. CrossRef
Multiparametric Photoacoustic Analysis of Human Thyroid Cancers In Vivo
Jeesu Kim, Byullee Park, Jeonghoon Ha, Idan Steinberg, Sarah M. Hooper, Chaiho Jeong, Eun-Yeong Park, Wonseok Choi, Tie Liang, Ja Seong Bae, Ravi Managuli, Yongmin Kim, Sanjiv S. Gambhir, Dong-Jun Lim, Chulhong Kim
Cancer Research.2021; 81(18): 4849. CrossRef
Thyroid Cancer Risk Factors in Children with Thyroid Nodules: A One-Center Study
Iwona Ben-Skowronek, Joanna Sieniawska, Emilia Pach, Wiktoria Wrobel, Anna Skowronek, Zaklina Tomczyk, Anna Mlodawska, Magdalena Makuch, Magdalena Malka, Czeslaw Cielecki, Pawel Nachulewicz
Journal of Clinical Medicine.2021; 10(19): 4455. CrossRef
Can We Predict Differentiated Thyroid Cancer Behavior? Role of Genetic and Molecular Markers
Rita Niciporuka, Jurijs Nazarovs, Arturs Ozolins, Zenons Narbuts, Edvins Miklasevics, Janis Gardovskis
Medicina.2021; 57(10): 1131. CrossRef
Recent Improvements in Genomic and Transcriptomic Understanding of Anaplastic and Poorly Differentiated Thyroid Cancers
Seong-Keun Yoo, Young Shin Song, Young Joo Park, Jeong-Sun Seo
Endocrinology and Metabolism.2020; 35(1): 44. CrossRef
Genomic and Transcriptomic Characteristics According to Size of Papillary Thyroid Microcarcinoma
Young Shin Song, Byung-Hee Kang, Seungbok Lee, Seong-Keun Yoo, Young Sik Choi, Jungsun Park, Dong Yoon Park, Kyu Eun Lee, Jeong-Sun Seo, Young Joo Park
Cancers.2020; 12(5): 1345. CrossRef
Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): Diagnostic updates and molecular advances
Ying-Hsia Chu, Peter M. Sadow
Seminars in Diagnostic Pathology.2020; 37(5): 213. CrossRef
Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy
María San Román Gil, Javier Pozas, Javier Molina-Cerrillo, Joaquín Gómez, Héctor Pian, Miguel Pozas, Alfredo Carrato, Enrique Grande, Teresa Alonso-Gordoa
International Journal of Molecular Sciences.2020; 21(14): 4951. CrossRef
DNA FISH Diagnostic Assay on Cytological Samples of Thyroid Follicular Neoplasms
Philippe Vielh, Zsofia Balogh, Voichita Suciu, Catherine Richon, Bastien Job, Guillaume Meurice, Alexander Valent, Ludovic Lacroix, Virginie Marty, Nelly Motte, Philippe Dessen, Bernard Caillou, Abir Ghuzlan, Jean-Michel Bidart, Vladimir Lazar, Paul Hofma
Cancers.2020; 12(9): 2529. CrossRef
Mechanisms of TERT Reactivation and Its Interaction with BRAFV600E
Young Shin Song, Young Joo Park
Endocrinology and Metabolism.2020; 35(3): 515. CrossRef
Utility of a multigene testing for preoperative evaluation of indeterminate thyroid nodules: A prospective blinded single center study in China
Yuntao Song, Guohui Xu, Tonghui Ma, Yanli Zhu, Hao Yu, Wenbin Yu, Wei Wei, Tianxiao Wang, Bin Zhang
Cancer Medicine.2020; 9(22): 8397. CrossRef
Thyroid Cancer and Circadian Clock Disruption
Roberta Malaguarnera, Caterina Ledda, Agnese Filippello, Francesco Frasca, Vincenzo Cristian Francavilla, Tiziana Ramaci, Maria Chiara Parisi, Venerando Rapisarda, Salvatore Piro
Cancers.2020; 12(11): 3109. CrossRef
Molecular testing approaches in thyroid cancer diagnosis
Abdul-Mohsen AlHejaily, Naji AlJohani
Journal of Biochemical and Clinical Genetics.2020; : 77. CrossRef

Original Articles

Clinical Study
Well-Differentiated Thyroid Cancer: The Philippine General Hospital Experience: Tom Edward N. Lo, Abigail T. Uy, Patricia Deanna D. Maningat; Endocrinol Metab. 2016;31(1):72-79. Published online March 16, 2016; DOI: https://doi.org/10.3803/EnM.2016.31.1.72

4,045 View
51 Download
20 Web of Science
14 Crossref

Abstract PDF PubReader

Background

Well-differentiated thyroid cancer (WDTC) is the most common form of thyroid malignancy. While it is typically associated with good prognosis, it may exhibit higher recurrence and mortality rates in selected groups, particularly Filipinos. This paper aims to describe the experience of a Philippine Hospital in managing patients with differentiated thyroid cancer.

Methods

We performed a retrospective cohort study of 723 patients with WDTC (649 papillary and 79 follicular), evaluating the clinicopathologic profiles, ultrasound features, management received, tumor recurrence, and eventual outcome over a mean follow-up period of 5 years.

Results

The mean age at diagnosis was 44±13 years (range, 18 to 82), with a majority of cases occurring in the younger age group (<45 years). Most tumors were between 2 and 4 cm in size. The majority of papillary thyroid cancers (PTCs, 63.2%) and follicular thyroid cancers (FTCs, 54.4%) initially presented as stage 1, with a greater proportion of FTC cases (12.7% vs. 3.7%) presenting with distant metastases. Nodal metastases at presentation were more frequent among patients with PTC (29.9% vs. 7.6%). A majority of cases were treated by complete thyroidectomy, followed by radioactive iodine therapy and thyroid stimulating hormone suppression, resulting in a disease-free state. Excluding patients with distant metastases at presentation, the recurrence rates for papillary and FTC were 30.1% and 18.8%, respectively.

Conclusion

Overall, PTC among Filipinos was associated with a more aggressive and recurrent behavior. FTC among Filipinos appeared to behave similarly with other racial groups.

Citations

Citations to this article as recorded by

Clinical, Histopathological, and Radiological Profile of Patients Presenting With Thyroid Malignancies Among the Kerala Population
Chandralal Prasannakumar Girijakumari , Arshad Koroth , Muhamed Fawas Abdul Rasheed , Azif Ali Usman, Shiraz Basheer, Mohamed Rasween Kareem
Cureus.2024;[Epub] CrossRef
Behaviour and epidemiology of differentiated thyroid cancer among filipinos in and outside the Philippines: Comparison between Qatar, Canada and Philippines
Mohamed Said Ghali, Walid El Ansari, Abdelrahman Abdelaal, Mohamed S. Al Hassan
Annals of Medicine and Surgery.2022; 81: 104202. CrossRef
Discrimination of malignant from benign thyroid lesions through neural networks using FTIR signals obtained from tissues
Abegail Santillan, Rock Christian Tomas, Ruth Bangaoil, Rolando Lopez, Maria Honolina Gomez, Allan Fellizar, Antonio Lim, Lorenzo Abanilla, Maria Cristina Ramos, Leonardo Guevarra, Pia Marie Albano
Analytical and Bioanalytical Chemistry.2021; 413(8): 2163. CrossRef
Decline in radioiodine use but not total thyroidectomy in thyroid cancer patients treated in the United Arab Emirates - A retrospective study
Malik Azhar, Faisal Aziz, Salama Almuhairi, Mohammad Alfelasi, Ali Elhouni, Rizwan Syed, Humaid O. Al-Shamsi, Khaled M. Aldahmani
Annals of Medicine and Surgery.2021; 64: 102203. CrossRef
Clinical predictors of I-131 therapy failure in differentiated thyroid cancer by machine learning: A single-center experience
David J. Lubin, Caleb Tsetse, Mohammad S. Khorasani, Massoud Allahyari, Mary McGrath
World Journal of Nuclear Medicine.2021; 20(03): 253. CrossRef
Differential Expression of Non-Coding RNA Signatures in Thyroid Cancer between Two Ethnic Groups
Kristiana Rood, Khodeza Begum, Hanmin Wang, Yan C. Wangworawat, Ryan Davis, Celina R. Yamauchi, Mia C. Perez, Alfred A. Simental, Ria T. Laxa, Charles Wang, Sourav Roy, Salma Khan
Current Oncology.2021; 28(5): 3610. CrossRef
The Role of postoperative external beam radiotherapy for differentiated thyroid carcinoma: A Systematic review and meta‐analysis
Luisa E. Jacomina, JC Kennetth M. Jacinto, Lester Bryan A. Co, Kelvin Ken L. Yu, Ryan Anthony F. Agas, Jayson L. Co, Michael Benedict A. Mejia
Head & Neck.2020; 42(8): 2181. CrossRef
Follicular thyroid cancer and Hürthle cell carcinoma: challenges in diagnosis, treatment, and clinical management
Giorgio Grani, Livia Lamartina, Cosimo Durante, Sebastiano Filetti, David S Cooper
The Lancet Diabetes & Endocrinology.2018; 6(6): 500. CrossRef
Poorly Differentiated Thyroid Carcinoma: 10-Year Experience in a Southeast Asian Population
Marc Gregory Yu, Jonathan Rivera, Cecilia Jimeno
Endocrinology and Metabolism.2017; 32(2): 288. CrossRef
Thyroid cancer mortality is higher in Filipinos in the United States: An analysis using national mortality records from 2003 through 2012
Michelle‐Linh T. Nguyen, Jiaqi Hu, Katherine G. Hastings, Eric J. Daza, Mark R. Cullen, Lisa A. Orloff, Latha P. Palaniappan
Cancer.2017; 123(24): 4860. CrossRef
Thyroid Fine-Needle Aspiration Practice in the Philippines
Agustina D. Abelardo
Journal of Pathology and Translational Medicine.2017; 51(6): 555. CrossRef
Articles inEndocrinology and Metabolismin 2016
Won-Young Lee
Endocrinology and Metabolism.2017; 32(1): 62. CrossRef
THYROID CANCER: A RETROSPECTIVE ANALYSIS
Javan N G, Jitendra N, Ibomcha Singh K H, Phungreikan N, Sanatomba Singh Y, Wormi Sharon
Journal of Evolution of Medical and Dental Sciences.2016; 5(40): 2456. CrossRef
Differentiated Thyroid Cancer in Asians
Bo Hyun Kim
Endocrinology and Metabolism.2016; 31(1): 62. CrossRef

Clinical Study
Risk Factors for Recurrence in Filipinos with Well-Differentiated Thyroid Cancer: Tom Edward Ngo Lo, Abigail Uy Canto, Patricia Deanna D. Maningat; Endocrinol Metab. 2015;30(4):543-550. Published online December 31, 2015; DOI: https://doi.org/10.3803/EnM.2015.30.4.543

3,624 View
51 Download
11 Web of Science
10 Crossref

Abstract PDF PubReader

Background

The incidence of well-differentiated thyroid cancer (WDTC) has increased in recent years. Despite its excellent prognosis, increasing morbidity from recurrent diseases continues to affect long-term outcomes. Among at-risk populations, Filipinos have the highest incidence of thyroid cancer worldwide, characterized by a highly aggressive and recurrent form of disease. Here, we sought to identify risk factors associated with disease recurrence among Filipinos with WDTC.

Methods

This retrospective cohort study examined 723 patients diagnosed with WDTC seen at Philippine General Hospital. Affected individuals were classified based on the presence or absence of disease recurrence. Multivariate logistic regression analyses were used to determine significant predictors of recurrence.

Results

Multiple risk factors, including age >45 years (odds ratio [OR], 1.44), multifocality of cancer (OR, 1.43), nodal involvement (OR, 4.0), and distant metastases at presentation (OR, 2.78), were significantly associated with a recurrence of papillary thyroid cancer (PTC). In contrast, follicular variant histology (OR, 0.60) and postsurgical radioactive iodine therapy (OR, 0.31) were protective for PTC recurrence. Distant metastases at presentation (OR, 19.4) and postsurgical radioactive iodine therapy (OR, 0.41) were associated with follicular thyroid cancer (FTC) recurrence.

Conclusion

Lymph node metastases at presentation was the strongest predictor of recurrence in PTC, whereas distant metastases at presentation was the strongest for FTC recurrence. Among Filipinos, stratification of WDTC patients based on recurrence risk factors identified in this study will be helpful in guiding the intensity of treatment strategies and long-term thyroid cancer surveillance.

Citations

Citations to this article as recorded by

Characterization of mortality and high-risk characteristics of thyroid cancer in Filipinos using the California Cancer Registry
Robert Hsu, Kai-Ya Tsai, Krithika Chennapan, Katherine Y. Wojcik, Alice W. Lee, Jorge J. Nieva, Lihua Liu
Frontiers in Public Health.2023;[Epub] CrossRef
Behaviour and epidemiology of differentiated thyroid cancer among filipinos in and outside the Philippines: Comparison between Qatar, Canada and Philippines
Mohamed Said Ghali, Walid El Ansari, Abdelrahman Abdelaal, Mohamed S. Al Hassan
Annals of Medicine and Surgery.2022; 81: 104202. CrossRef
Risk Factors for Recurrence of Follicular Thyroid Cancer: A Systematic Review
Mathias Peter Grønlund, Jakob Schmidt Jensen, Christoffer Holst Hahn, Christian Grønhøj, Christian von Buchwald
Thyroid.2021;[Epub] CrossRef
Differential Expression of Non-Coding RNA Signatures in Thyroid Cancer between Two Ethnic Groups
Kristiana Rood, Khodeza Begum, Hanmin Wang, Yan C. Wangworawat, Ryan Davis, Celina R. Yamauchi, Mia C. Perez, Alfred A. Simental, Ria T. Laxa, Charles Wang, Sourav Roy, Salma Khan
Current Oncology.2021; 28(5): 3610. CrossRef
Dynamic Risk Stratification for Predicting Treatment Response in Differentiated Thyroid Cancer
Evanthia Giannoula, Christos Melidis, Nikitas Papadopoulos, Panagiotis Bamidis, Vasilios Raftopoulos, Ioannis Iakovou
Journal of Clinical Medicine.2020; 9(9): 2708. CrossRef
Overall Survival of Papillary Thyroid Carcinoma Patients: A Single‐Institution Long‐Term Follow‐Up of 5897 Patients
Yasuhiro Ito, Akira Miyauchi, Minoru Kihara, Mitsuhiro Fukushima, Takuya Higashiyama, Akihiro Miya
World Journal of Surgery.2018; 42(3): 615. CrossRef
Prognostic value of the 8^th edition of the tumor-node-metastasis classification for patients with papillary thyroid carcinoma: a single-institution study at a high-volume center in Japan
Yasuhiro Ito, Akira Miyauchi, Mitsuyoshi Hirokawa, Masatoshi Yamamoto, Hitomi Oda, Hiroo Masuoka, Hisanori Sasai, Mitsuhiro Fukushima, Takuya Higashiyama, Minoru Kihara, Akihiro Miya
Endocrine Journal.2018; 65(7): 707. CrossRef
The correlations between DNA methylation and polymorphisms in the promoter region of the human telomerase reverse transcriptase (hTERT) gene with postoperative recurrence in patients with thyroid carcinoma (TC)
Jian-Jun Li, Ping Chen Jue-Ru Zheng, Yao-Zong Wang
World Journal of Surgical Oncology.2017;[Epub] CrossRef
Differentiated Thyroid Cancer in Asians
Bo Hyun Kim
Endocrinology and Metabolism.2016; 31(1): 62. CrossRef
Meta-analysis of radiofrequency ablation for treating the local recurrence of thyroid cancers
Q. Zhao, G. Tian, D. Kong, T. Jiang
Journal of Endocrinological Investigation.2016; 39(8): 909. CrossRef

Frequency of RAS Mutations and PAX8/PPARgamma Rearrangement in Follicular Thyroid Tumors in Korea.: Hye Jeong Kim, Hye Won Jang, Seo Young Sohn, Yoon La Choi, Hee Jin Kim, Young Lyun Oh, Sun Wook Kim, Jae Hoon Chung; Endocrinol Metab. 2012;27(1):45-53. Published online March 1, 2012; DOI: https://doi.org/10.3803/EnM.2012.27.1.45

22,691 View
22 Download
3 Crossref

Abstract PDF

BACKGROUND
Follicular thyroid tumors harbor several genetic alterations such as RAS mutations and PAX8/PPARgamma rearrangement. The aims of our study were to investigate the prevalence of RAS mutations and PAX8/PPARgamma rearrangement in follicular thyroid tumors and to correlate RAS mutations and/or PAX8/PPARgamma rearrangement with clinicopathologic features in Korean patients with follicular thyroid carcinomas. METHODS: RAS mutations were investigated by polymerase chain reaction and DNA sequencing in surgical specimens of 37 follicular thyroid carcinomas (FTCs) and 16 follicular thyroid adenomas (FTAs). PAX8/PPARgamma rearrangement was analyzed by fluorescent in situ hybridization in surgical specimens of 31 FTCs and 13 FTAs. RESULTS: RAS mutations were detected in 30% (11 of 37) of FTCs and 19% (three of 16) of FTAs. Three of 11 FTC patients with RAS mutations died of thyroid cancer, but none of the 26 FTC patients without RAS mutations. PAX8/PPARgamma rearrangement was found in 10% (three of 31) of FTCs, but in none of the 13 FTAs. All three FTC patients with PAX8/PPARgamma rearrangement remained in complete remission during follow-up. There were no FTC patients with both RAS mutations and PAX8/PPARgamma rearrangement. CONCLUSION: The prevalence of RAS mutations in our series of follicular tumors was similar to previous studies. The frequency of PAX8/PPARgamma rearrangements in our group of FTC was lower than previous western reports, but higher than Japanese reports. RAS mutations may be associated with hematogeneous metastasis and poor survival while PAX8/PPARgamma rearrangement may be related to more favorable prognosis in Korean patients with FTCs.

Citations

Citations to this article as recorded by

Preoperative serum thyroglobulin and changes in serum thyroglobulin during TSH suppression independently predict follicular thyroid carcinoma in thyroid nodules with a cytological diagnosis of follicular lesion
Hye Jeong Kim, Ji-Oh Mok, Chul Hee Kim, Yeo Joo Kim, Sang Jin Kim, Hyeong Kyu Park, Dong Won Byun, Kyoil Suh, Myung Hi Yoo
Endocrine Research.2017; 42(2): 154. CrossRef
Mutation Profile of Well-Differentiated Thyroid Cancer in Asians
Young Shin Song, Jung Ah Lim, Young Joo Park
Endocrinology and Metabolism.2015; 30(3): 252. CrossRef
Analysis of RAS mutation and PAX8/PPARγ rearrangements in follicular-derived thyroid neoplasms in a Korean population: frequency and ultrasound findings
S. H. Jeong, H. S. Hong, J. J. Kwak, E. H. Lee
Journal of Endocrinological Investigation.2015; 38(8): 849. CrossRef

Postoperative Findings of the Cytological Diagnosis of Follicular Neoplasm or Hurthle Cell Neoplasm and the Risk of Malignancy.: Ji Hye Yim, Eui Young Kim, Won Gu Kim, Tae Yong Kim, Gyungyup Gong, Suck Joon Hong, Won Bae Kim, Young Kee Shong; Endocrinol Metab. 2010;25(4):316-320. Published online December 1, 2010; DOI: https://doi.org/10.3803/EnM.2010.25.4.316

2,081 View
31 Download
4 Crossref

Abstract PDF

BACKGROUND
Follicular neoplasm (FN) or Hurthle cell neoplasm (HN) is a less well understood pitfall when evaluating thyroid nodule with fine-needle aspiration (FNA). This study aimed to determine the rates of malignancy and the predictive factors for malignancy in thyroid nodules with a cytological diagnosis of FN or HN. METHODS: The patients who were cytologically diagnosed as having FN or HN after FNA between 1995 and 2004 at Asan Medical Center were included in this study. We collected the pathology data until 2009 and we analyzed the clinical characteristics associated with malignancy. RESULTS: A total 478 patients were cytologically diagnosed as having FN or HN during the study period and 327 (68%) among them underwent thyroid surgery. Thyroid malignancy was confirmed in 157 (48%) of 327 patients. Malignancy was confirmed in 124 patients with FN (124/253, 49%). They were 48 papillary, 65 follicular, 7 Hurthle cell and 3 medullary carcinomas and 1 anaplastic carcinoma. The malignancy in the cases of HN (33/71, 44.6%) was 9 papillary, 4 follicular and 20 Hurthle cell carcinomas. The risk of malignancy was not associated with male gender, a larger tumor size (> 4 cm) or the diagnosis of HN. However, an age below 20 years (RR 3.6, P = 0.03) and above 60 years (RR 2.3, P = 0.04) was associated with an increased risk of malignancy. CONCLUSION: About half of the patients with FN or HN on FNA cytology were diagnosed as having thyroid cancer after surgery. The malignancy rate for the cytologic diagnosis of HN was similar to that for FN. Thyroid surgery should be recommended for this situation, and especially for patients younger than 20 years or older than 60 years.

Citations

Citations to this article as recorded by

Diagnostic Value of Preoperative Serum Thyroglobulin Measurement for the Diagnosis of Malignancy in Follicular or Hürthle Cell Neoplasms of the Thyroid Gland
Nam Kyu Kim, Seong Joo Kang, Weon Hyoung Lee, Go Eun Yeo, You Jin Han, Bu Kyung Kim, Su Kyoung Kwon, Yo-Han Park, Young Sik Choi
Kosin Medical Journal.2014; 29(1): 17. CrossRef
Fine Needle Aspiration Cytology of Thyroid Follicular Neoplasm: Cytohistologic Correlation and Accuracy
Changyoung Yoo, Hyun Joo Choi, Soyoung Im, Ji Han Jung, Kiouk Min, Chang Suk Kang, Young-Jin Suh
Korean Journal of Pathology.2013; 47(1): 61. CrossRef
Predictive Factors of Malignancy in Thyroid Nodules with a Cytological Diagnosis of Follicular Neoplasm
Seong Hyeon Lee, Jeong Su Baek, Joo Young Lee, Jung Ah Lim, Soo Youn Cho, Tae Hyun Lee, Yun Hyi Ku, Hong Il Kim, Min Joo Kim
Endocrine Pathology.2013; 24(4): 177. CrossRef
Postoperative Findings of the Cytological Diagnosis of Follicular Neoplasm or Hürthle Cell Neoplasm and Risk of Malignancy
Jung Uee Lee, Minho Shong
Endocrinology and Metabolism.2010; 25(4): 298. CrossRef

Case Reports

A Case of Follicular Thyroid Carcinoma Associated with Hemiagenesis of Thyroid Gland.: Bu Kyung Kim, Hyun Joo Jung, Ye Na Kim, Young Sik Choi, Yo Han Park, Hee Kyoung Chang, Jeong Hoon Kim; J Korean Endocr Soc. 2010;25(1):46-49. Published online March 1, 2010; DOI: https://doi.org/10.3803/jkes.2010.25.1.46

1,908 View
24 Download
1 Crossref

Abstract PDF

Thyroid hemiagenesis is a rare congenital anomaly, in which one thyroid lobe fails to develop. Thyroid hemiagenesis is associated with thyroid diseases such as Graves' disease, Hashimoto's thyroiditis, colloidal goiter and thyroid follicular and papillary cancer. A 53-year-old female patient was diagnosed with a thyroid nodule on health examination. A 99mTc pertechnetate thyroid scan showed absent uptake in the left lobe and cold nodule on the right lobe of thyroid gland. By ultrasonography, we found hemiagenesis in the left thyroid gland and an irregular shaped thyroid nodule on the right lobe of thyroid gland. We performed ultrasonography guided fine needle aspiration and cytologic analysis showed indeterminate nature. Thyroidectomy was performed and finally diagnosed follicular carcinoma of thyroid gland. The authors report this case with a literature review.

Citations

Citations to this article as recorded by

A Case of Thyroid Hemiagenesis with Concurrent Papillary Thyroid Carcinoma
Ye-Mo Nam, June Sik Park, Kyung Jin Na, Dongbin Ahn
Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2011; 54(8): 557. CrossRef

A Case of Thyroid Microcarcinoma with Multiple Metastases, Including Liver Metastasis.: Sang Jin Lee, Won Gu Kim, Hyung Yong Kim, Hyun Gi Lee, Tae Yong Kim, Youn Suck Koh; J Korean Endocr Soc. 2007;22(1):50-54. Published online February 1, 2007; DOI: https://doi.org/10.3803/jkes.2007.22.1.50

1,559 View
17 Download

Abstract PDF: A 65-year-old woman presented with a dry cough and multiple various sized nodules in both lungs on chest X-ray. A CT scan showed a 9.5 cm sized hypervascular mass in the liver and a 5.5 cm sized intraabdominal mass. A percutaneous needle biopsy of one of the lung nodules revealed a metastatic follicular thyroid carcinoma. Therefore, thyroid ultrasonography was performed, which revealed a 1 cm sized nodule in the right thyroid lobe. Cytology, obtained by ultrasonography guided fine needle aspiration, revealed a follicular neoplasm. The tumor cells were weakly positive on galectin-3 immunostaining, which favored a follicular carcinoma. An ultrasonography guided biopsy of the liver and EUS (endoscopic ultrasonography)-guided biopsy of the intraabdominal mass revealed a metastatic follicular thyroid carcinoma in the liver and peritoneum. We report a very rare case of a follicular thyroid microcarcinoma, with multiple metastases to the lung, liver and peritoneum.

A Case of Follicular Thyroid Carcinoma Developed in Pendred Syndrome.: So Hun Kim, Ji Young Jung, Sung Jae Shin, So Young Park, Si Hoon Lee, Yoo Mee Kim, Yu Mie Rhee, Soon Won Hong, Bong Soo Cha, Chul Woo Ahn, Kyung Rae Kim, Sung Kil Lim, Hyun Chul Lee; J Korean Endocr Soc. 2004;19(4):411-418. Published online August 1, 2004

1,052 View
22 Download

Abstract PDF: Pendred syndrome is an autosomal recessive genetic disorder, which is characterized by sensorineural hearing loss, goiter and a positive perchlorate discharge test. It is caused by mutations of the PDS gene, and its clinical characteristics vary widely. The thyroid function in most cases is normal, or shows only mild hypothyroidism. In Pendred syndrome, there is an organification defect that leads to defective thyroid hormone synthesis, followed by chronic TSH stimulation. Herein is reported a case of a follicular thyroid carcinoma associated with Pendred syndrome. To our knowledge, this is the first case reported in Korea. The patient presented with a huge anterior neck mass, sensorineural hearing loss and a positive perchlorate discharge test. Fine needle aspiration cytology suggested malignancy of the thyroid, and a total thyroidectomy, with central compartment node dissection, was performed. The pathology from the thyroid mass showed a poorly differentiated follicular thyroid carcinoma

Original Articles

The Efficacy of Thyroxine Suppression Therapy in Benign Thyroid Nodules.: Seog Ki Yun, Chul Hee Kim, Young Sun Kim, Dong Won Byun, Kyo Il Suh, Myung Hi Yoo; J Korean Endocr Soc. 2000;15(4-5):532-541. Published online January 1, 2001

1,158 View
22 Download

Abstract PDF: BACKGROUND
Benign pathologic findings are shown in 800% of thyroid nodules by fine needle aspiration cytology (FNAC) or needle biopsy. About half of these benign nodules are follicular lesions which are presented only as thyroid follicles or thyroid cell clumps. Differential diagnosis of follicular adenoma, follicular carcinoma and adenomatous goiter is impossible by FNAC or needle biopsy. Thyroxine suppression therapy has been performed traditionally in order to discriminate malignant nodules, but few studies are available which confirmed the efficacy of thyroxine suppression therapy in thyroid nodules of those the initial pathologic findings were follicular lesions. So we tried to evaluate the efficacy of thyroxine suppression therapy in benign thyroid nodules and also the incidence of thyroid cancer of the thyroid nosules which were not decreased on thyroxine suppression therapy after surgical resection. METHODS: Total 1027 patients with thyroid nodules were evaluated by FNAC or needle biopsy at Soonchunhyang university hospital from 1990 to 1996. Among 1027 patients, 507 patients showed follicular lesions in FNAC or needle biopsy and they received thyroxine suppression therapy. Thyroid nodule volume was measured before and after thyroxine suppression therapy using ultrasonography. We studied 184 patients who were followed up for more than 1 year. Serial changes of thyroid function tests, thyroid nodule volume, serum thyroglubulin (Tg) level before and after therapy were analyzed. RESULTS: l. In 80 (43.5%) of the 184 patients, nodule volumes decreased more than 50 percent after thyroxine suppression therapy. 2. There was no significant difference in serum T3, T4, TSH levels before and after thyroxine suppression therapy between group I (nodule volume decreased less than 50%) and group II (nodule volume decreased more than 50%). 3. In group II patients, thyroid nodule volumes were decreased continuously at 12 month, 18 month and 30 month after thyroxine suppression (p<0.05). 4. There was no significant difference between the group I and group II in the frequency of multiple thyroid nodules on ultrasonography. 5. Among 37 patients who underwent thyroidectomy, 19 cases (51.4%) were revealed as malignant thyroid nodules (papillary cancer 4 cases, follicular cancer 15 cases). Eighteen cases (48.6%) were revealed as benign thyroid nodules (follicular adenoma 10 cases, adenomatous goiter 8 cases). 6. There was no significant difference in the frequency of multiple nodules on ultrasonography between benign and malignant nodules. CONCLUSION: Our data suggested thyroxine suppression therapy was effective in discriminating malignant thyroid nodules from benign nodules, especially in selecting follicular carcinoma from follicular lesion by FNAC or biopsy.

The Clinical Utility of HBME - 1 Immunostaining in the Diagnosis of Follicular Carcinoma of Thyroid.: Young Goo Shin, Kyi Bum Lee, Yoon Sok Chung, Hyeon Man Kim; J Korean Endocr Soc. 2000;15(4-5):513-521. Published online January 1, 2001

870 View
17 Download

Abstract PDF: BACKGROUND
Currently, in follicular lesion of aspirates of thyroid, pathologic evaluation of surgical specimen is the only diagnostic method whether the patient had follicular thyroid malignancy or not. The aim of this study is the evaluation of the clinical utility of HBME-1 immunostaining in the diagnosis of follicular thyroid malignancy in surgical specimen, and to establish the diagnostic guideline of HBME-1 immunostaining. METHODS: From 1994 to Sep. 1999, the 72 paraffin embedded tissue, which was already diagnosed as thyroid follicular carcinoma or adenoma through the pathologic evaluation of surgical specimen, were studied. Among 72 specimens, the 29 follicular carcinoma were included, and the others were follicular adenoma. The specimens were stained with HBME-1 monoclonal antibody by standard avidin-biotin peroxidase complex methods. One limited pathologist had read the findings of the immunostaining with a basis such as percent of tumor area. These percentage were divided to 4 grade as follows: 1) Grade 0: negative stained, 2) Grade 1: stained area < 30%, 3) Grade 2: 30 < or = stained area < 60%, and 4) Grade 3: stained area > or = 60%. After we had set a basis of follicular carcinoma as more than Grade 2, defined the clinical utility of HBME-1 immunostaining. The clinical utility was based that the concordance rate between pathologic diagnosis and the findings of immunostaining was more than 80% in both groups. RESULTS: 1) There was significant difference between two groups in intensity of cellular staining (p=0.04, x2). But, there might not be helpful to rule out follicular carcinoma of thyroid from adenoma in fine-needle aspirates. 2) In both groups, the percent of stained area of tumor was very diverse from 0% to 100%, and was statistically significant different (p=0.007). 3) Because the only 5 cases of normal tissue in both groups were stained weakly, the HBME-1 immunostaining was like to specific reaction with tumor tissue in both groups. 4) When we had set a basis of follicular thyroid carcinoma as more than Grade 2 (> or = 30%), the concordance rate between pathologic diagnosis and the findings of immuno- staining was 69.7% in follicular adenoma, 65.5% in follicular carcinoma, respectively. CONCLUSION: The HBME-1 immunostaining may not be help to differentiate follicular carcinoma from adenoma.

Allelotyping and Comparative Genomin Hybridization Studies in Papillary Thyroid Carcinomas and Follicular Adenomas.: Il Min Ahn, Eun Sook Kim, Hyun Soo Park, Ki Young Park, Seok Jun Hong, Kyung Yub Gong, Jin Yub Kim, Sung Bae Kim, Sang Hee Kim, Sung Jin Lee, Jung Hee Han, Kwan Ja Jee; J Korean Endocr Soc. 1999;14(2):314-322. Published online January 1, 2001

1,161 View
17 Download

Abstract PDF: BACKGROUND
In our previous study, the prevalence of the known causes of thyroid tumorigenesis was relatively rare in Korean population, suggesting genetic and environmental differences exist. Screening of genetic alteration in papillary thyroid carcinoma(PTC) and follicular adenoma(FA) in whole genomic scale was needed prior to search on individual genes of possible causes. METHODS: Ten cases of PTC without ret/PTC-I, -2, -3 rearrangement and 5 cases of follicular adenoma were included in the study of microsatellite marker allelotyping. Sixty two microsatellite markers available, were chosen to cover the known sites of loss of heterozygosity(LOH) involved in thyroid tumors, tumor suppressor genes and terminal portion of each chromosomes. PCR was performed on tumor DNA and leukocytes DNA from each patient with MDE gel electrophoresis to detect LOH. Same specitnens as above, 3 case of normal thyroid tissues and NPA, ARO cell lines were included in the study of comparative genomic hybridization(CGH). Tumor and control DNAs were hybridized to metaphase chromosome with differential stainings with fluorescein and rhoda-mine-dUTP. Obtained results were analyzed by multicolor fluorescence computer assisted image analyzer. RESULTS: In allelotyping, LOH were detected in 5 cases of PTC, 2 cases on D10S1435, 1 case each on D2S1780, DSS1099, D11S1986, D16S539, 1 case of PTC revealed LOH on DSS1099, D11S1986. In FA, LOH were detected in 3 cases on D1S534, D1S226, Dl 1S907, D22S683, DXS9807. In CGH, Xp addition was noticed in 1 case of PTC, 12q and 10p addition was noticed in 1 case each, 16q deletion and 17q addition in 1 case of FA. CONCLUSION: No hot spot of LOH was noticed in microsatellite marker allelotyping, neither of common chromosomal change in CGH study suggesting unbalanced translocation or gene amplification more than 5-10 Mb may be involved in the genetic alteration of PTC and FA.

First
Prev
Page of 1
Next
Last

Search